KBP Biosciences CEO and leadership

Fred Yang is an Adjunct Associate Professor, Medical School at Drexel University; Chief Development Officer/Senior Vice President at KBP Biosciences; and Founder and Principle at InnoMed Consulting and is based in Washington, D.C.. He has worked as Head, Diabetes & Metabolic Disease, Biostat and Informatics; at ASTRAZENECA PLC; Informetics at GSK; and Head of BDS, Alternative Development Program; at GSK. Fred studied at University of Wisconsin Madison between 1990 and 1991, Peking University between 1980 and 1984, and University of Wisconsin Madison between 1991 and 1996.

Robert Segal is a Deputy Chief Medical Officer at KBP Biosciences.

Douglas Losordo joined Longeveron’s Board of Directors in 2021 as part of Longeveron’s Corporate Conversion. Dr. Losordo has worked in the biotech industry developing cell-based therapies for over twenty years, most recently serving as Executive Vice President, Head of Research and Development and Chief Medical Officer of KBP Biosciences Inc. Dr. Losordo was previously the Executive Vice President, Global Head of Research and Development, Chief Medical Officer of Caladrius Biosciences (Nasdaq: CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse chronic disease, from August 2013 until November 2020. Dr. Losordo has extensive knowledge of clinical, regulatory, manufacturing, supply chain and commercial factors unique to cellular therapy technologies as a result of his prior industry experience. Dr. Losordo’s also previously served as a Professor of Medicine at NYU Langone Medical Center and Northwestern University’s Feinberg School of Medicine. He received his MD from the University of Vermont College of Medicine, and his B.A. in Zoology from the University of Vermont.

Fred Yang is an Adjunct Associate Professor, Medical School at Drexel University; Chief Development Officer/Senior Vice President at KBP Biosciences; and Founder and Principle at InnoMed Consulting and is based in Washington, D.C.. He has worked as Head, Diabetes & Metabolic Disease, Biostat and Informatics; at ASTRAZENECA PLC; Informetics at GSK; and Head of BDS, Alternative Development Program; at GSK. Fred studied at University of Wisconsin Madison between 1990 and 1991, Peking University between 1980 and 1984, and University of Wisconsin Madison between 1991 and 1996.

Robert Segal is a Deputy Chief Medical Officer at KBP Biosciences.